Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study
Sponsor: Genentech, Inc.
Summary
This was a multicenter, open-label extension study. Patients who received vismodegib (GDC-0449) in a Genentech-sponsored study and who had completed the parent study or who continued to receive vismodegib at the time the parent study closed were eligible for continued treatment in this protocol.
Official title: An Open-Label, Multicenter Extension Study of GDC-0449 (Hedgehog Pathway Inhibitor) in Patients Treated With GDC-0449 in a Previous Genentech-sponsored Phase I or Phase II Cancer Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
19
Start Date
2009-09-03
Completion Date
2014-01-09
Last Updated
2026-05-08
Healthy Volunteers
No
Interventions
Vismodegib
Vismodegib was supplied in capsules.
FOLFOX
FOLFOX (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and oxaliplatin \[OX\]) was supplied as solutions for intravenous administration.
FOLFIRI
FOLFIRI (folinic acid \[FOL, leucovorin\], fluorouracil \[F, 5-FU\], and irinotecan \[IRI\]) was supplied as solutions for intravenous administration.
Bevacizumab
Bevacizumab was supplied as a solution for intravenous administration.
Locations (10)
TGen Clinical Research Srvs
Scottsdale, Arizona, United States
Children's Hospital
Oakland, California, United States
Comprehensive Cancer Care
Palm Springs, California, United States
Stanford Univ Medical Center
Stanford, California, United States
Johns Hopkins Univ Med Center
Baltimore, Maryland, United States
University Of Michigan
Ann Arbor, Michigan, United States
Karmanos Cancer Institute..
Detroit, Michigan, United States
Nevada Cancer Research Foundation
Las Vegas, Nevada, United States
Irfan Firdaus, D.O.
Cincinnati, Ohio, United States
DermSurgery Associates, PA
Houston, Texas, United States